Franz Humer, CEO of Roche, has to decide whether to mount a hostile tender offer of shares owned biotechnology subsidiary Roche, Genentech. The case provides an opportunity to analyze the company's strategy in relation to Roche Genentech, the pros and cons of combining two companies with different cultures, the cost of Genentech, and tactics of hostile tender offer. "Hide
by Carliss Y. Baldwin, Bo Becker, Vincent Dessain Source: Harvard Business School 32 pages. Publication Date: February 26, 2010. Prod. #: 210040-PDF-ENG
Related Case Solutions & Analyses:
Ducati
Howard Schultz and Starbucks Coffee Company
ICICI Banks Credit Card: Journey to Asian Leadership
iMergent (B)
Managerial Overview of Open Source Software
Discipline of Teams: Tallahassee Democrat Elite Team Video (DVD)
Corporate Governance
Dirigo International
ABC COST ANALYSIS/INSTALLATION OF A PLAN IN A NURSING HOME GROUP
Negotiation and Cross-Culture Management – Coca-Cola
